These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1509684)

  • 1. Imprint coding on solid medication forms: problems in interpretation.
    Smolinske SC; Robertson WO
    Vet Hum Toxicol; 1992 Apr; 34(2):170-2. PubMed ID: 1509684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoiding medication mixups. Identifiable imprint codes.
    Vasudevan P; Del Gianni T; Robertson WO
    West J Med; 1996 Dec; 165(6):352-4. PubMed ID: 9000855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A needed technical fix?
    Robertson WO
    Vet Hum Toxicol; 2000 Apr; 42(2):118-9. PubMed ID: 10750184
    [No Abstract]   [Full Text] [Related]  

  • 4. Current FDA policy on use of human-labeled drugs in animals.
    Teske RH
    J Am Vet Med Assoc; 1993 May; 202(10):1632-3;discussion 1634. PubMed ID: 8514570
    [No Abstract]   [Full Text] [Related]  

  • 5. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
    Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications for the FDA/Center for Veterinary Medicine (CVM).
    Geyer RE
    J Am Vet Med Assoc; 1993 May; 202(10):1718-23. PubMed ID: 8514592
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA regulatory compliance reconsidered.
    Tobias C
    Cornell Law Rev; 2008 Jul; 93(5):1003-38. PubMed ID: 18618969
    [No Abstract]   [Full Text] [Related]  

  • 9. Labeling and manufacturing standards proposed for all dietary supplements.
    Horrigan B; Block B
    Altern Ther Health Med; 2003; 9(3):22. PubMed ID: 12776471
    [No Abstract]   [Full Text] [Related]  

  • 10. Compounding forum: FDA-CVM hears veterinarians' views.
    J Am Vet Med Assoc; 1993 Nov; 203(10):1367-72. PubMed ID: 8276690
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA in hot water again over cost of proposed drug labeling rule.
    Demkovich LE
    Natl J (Wash); 1979 Sep; 11(38):1568-70. PubMed ID: 10243426
    [No Abstract]   [Full Text] [Related]  

  • 14. The FDA at work: cutting-edge science promoting public health.
    Hilts PJ
    FDA Consum; 2006; 40(1):28-35, 39-41. PubMed ID: 16528824
    [No Abstract]   [Full Text] [Related]  

  • 15. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediculicide drug products for over-the-counter human use; amendment of final monograph. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(250):75414-8. PubMed ID: 14986677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to comments on the proposed model of a professional drug label.
    Martinez MN; Brown SA; Copeland DD; Haibel GK; Koritz GD; Riddell MG; Riviere JE; Rollins LD
    J Am Vet Med Assoc; 1996 Dec; 209(12):2068-70. PubMed ID: 8960188
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA, off-label use, and informed consent: debunking myths and misconceptions.
    Beck JM; Azari ED
    Food Drug Law J; 1998; 53(1):71-104. PubMed ID: 11795338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.